Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
F 78.35 0.10% 0.08
RETA closed up 0.1 percent on Friday, May 14, 2021, on 1.14 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical RETA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.10%
New Downtrend Bearish 0.10%
New 52 Week Low Weakness 0.10%
Multiple of Ten Bearish Other 0.10%
Wide Bands Range Expansion 0.10%
Older End-of-Day Signals for RETA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 2 days ago
Lower Bollinger Band Support 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago
Up 1% 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Reata Pharmaceuticals, Inc. - Class A Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biology Clinical Development Diseases Inflammation Health Care Hypertension Pulmonary Arterial Hypertension Transcription Myopathy Transcription Factors Antioxidant Pulmonary Hypertension Oxidative Stress Transcription Factor Ataxia Friedreich's Ataxia Mitochondria Interstitial Lung Disease

Is RETA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 186.8165
52 Week Low 76.34
Average Volume 320,079
200-Day Moving Average 116.20
50-Day Moving Average 99.74
20-Day Moving Average 91.40
10-Day Moving Average 86.76
Average True Range 5.52
ADX 26.43
+DI 13.25
-DI 33.51
Chandelier Exit (Long, 3 ATRs ) 93.44
Chandelier Exit (Short, 3 ATRs ) 92.90
Upper Bollinger Band 107.18
Lower Bollinger Band 75.63
Percent B (%b) 0.09
BandWidth 34.52
MACD Line -5.09
MACD Signal Line -3.68
MACD Histogram -1.4078
Fundamentals Value
Market Cap 2.28 Billion
Num Shares 29.1 Million
EPS -4.06
Price-to-Earnings (P/E) Ratio -19.32
Price-to-Sales 589.00
Price-to-Book 27.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 83.24
Resistance 3 (R3) 83.11 81.36 82.43
Resistance 2 (R2) 81.36 80.11 81.42 82.15
Resistance 1 (R1) 79.85 79.34 80.61 79.98 81.88
Pivot Point 78.10 78.10 78.47 78.16 78.10
Support 1 (S1) 76.59 76.85 77.35 76.72 74.82
Support 2 (S2) 74.84 76.08 74.90 74.55
Support 3 (S3) 73.33 74.84 74.28
Support 4 (S4) 73.46